Changing  	Changing  	 VBG	O
the  	the  	 DT	O
paradigm  	paradigm  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
recurrent  	recurrent  	 JJ	I-NP
ovarian  	ovarian  	 JJ	I-NP
cancer 	cancer 	 NN	I-NP
:  	:  	 :	O
from  	from  	 IN	O
platinum  	platinum  	 NN	O
doublets  	doublets  	 NN	O
to  	to  	 TO	O
nonplatinum  	nonplatinum  	 VB	O
doublets  	doublets  	 NNS	O
and  	and  	 CC	O
adding  	adding  	 VBG	B-NP
antiangiogenesis  	antiangiogenesis  	 NNS	I-NP
compounds  	compounds  	 VBP	O
The  	The  	 DT	O
optimal  	optimal  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
for  	for  	 IN	O
women  	women  	 NNS	O
with  	with  	 IN	O
recurrent  	recurrent  	 JJ	O
epithelial  	epithelial  	 JJ	B-NP
ovarian  	ovarian  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
is  	is  	 VBZ	O
evolving 	evolving 	 VBG	O
.  	.  	 .	O
The  	The  	 DT	O
objective  	objective  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
review  	review  	 NN	O
is  	is  	 VBZ	O
to  	to  	 TO	O
outline  	outline  	 VB	O
the  	the  	 DT	O
transition  	transition  	 NN	O
away  	away  	 RB	O
from  	from  	 IN	O
platinum  	platinum  	 NN	O
doublets  	doublets  	 NN	O
toward  	toward  	 IN	O
nonplatinum  	nonplatinum  	 JJ	B-NP
combinations  	combinations  	 NNS	I-NP
and  	and  	 CC	O
review  	review  	 VB	O
emerging  	emerging  	 VBG	B-NP
data  	data  	 NNS	I-NP
on  	on  	 IN	O
antiangiogenesis  	antiangiogenesis  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
.  	.  	 .	O
Recently  	Recently  	 RB	O
published  	published  	 VBN	O
and  	and  	 CC	O
presented  	presented  	 VBN	O
data  	data  	 NNS	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
ongoing  	ongoing  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
are  	are  	 VBP	O
discussed 	discussed 	 VBN	O
.  	.  	 .	O
Current  	Current  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
practice  	practice  	 NN	I-NP
largely  	largely  	 RB	O
harmonizes  	harmonizes  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
paradigm  	paradigm  	 NN	O
that  	that  	 WDT	O
outlines  	outlines  	 VBZ	O
a  	a  	 DT	O
treatment  	treatment  	 NN	B-NP
algorithm  	algorithm  	 NN	I-NP
for  	for  	 IN	O
recurrent  	recurrent  	 JJ	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
duration  	duration  	 NN	O
of  	of  	 IN	O
platinum-free  	platinum-free  	 JJ	B-NP
exposure 	exposure 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
model 	model 	 NN	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
whose  	whose  	 WP$	O
penultimate  	penultimate  	 JJ	O
platinum  	platinum  	 NN	B-NP
compound  	compound  	 NN	I-NP
exposure  	exposure  	 NN	I-NP
( 	( 	 -LRB-	O
platinum-free  	platinum-free  	 JJ	B-NP
interval  	interval  	 NNS	I-NP
[ 	[ 	 -LRB-	O
PFI 	PFI 	 NNP	B-NP
] 	] 	 -RRB-	O
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
longer  	longer  	 RB	O
than  	than  	 IN	O
6  	6  	 CD	O
months  	months  	 NNS	O
are  	are  	 VBP	O
generally  	generally  	 RB	O
offered  	offered  	 VBN	O
a  	a  	 DT	O
platinum  	platinum  	 NN	B-NP
agent  	agent  	 NN	I-NP
or  	or  	 CC	O
a  	a  	 DT	O
platinum-containing  	platinum-containing  	 JJ	O
doublet 	doublet 	 NN	O
;  	;  	 :	O
those  	those  	 DT	O
with  	with  	 IN	O
a  	a  	 DT	O
shorter  	shorter  	 JJR	O
interval  	interval  	 NNS	O
are  	are  	 VBP	O
usually  	usually  	 RB	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
nonplatinum  	nonplatinum  	 JJ	B-NP
agent 	agent 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
simple  	simple  	 JJ	O
contention  	contention  	 NN	O
that  	that  	 IN	O
better  	better  	 JJR	O
clinical  	clinical  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
will  	will  	 MD	O
be  	be  	 VB	O
realized  	realized  	 VBN	O
with  	with  	 IN	O
platinum  	platinum  	 NN	O
in  	in  	 IN	O
those  	those  	 DT	O
deemed  	deemed  	 JJ	O
platinum  	platinum  	 NN	O
sensitive  	sensitive  	 JJ	O
( 	( 	 -LRB-	O
PFI  	PFI  	 NNP	B-NP
> 	> 	 CD	O
6  	6  	 CD	O
months 	months 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
becoming  	becoming  	 VBG	O
clear  	clear  	 JJ	O
from  	from  	 IN	O
various  	various  	 JJ	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
and  	and  	 CC	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
that  	that  	 IN	O
the  	the  	 DT	O
performance  	performance  	 NN	O
of  	of  	 IN	O
many  	many  	 JJ	O
nonplatinum  	nonplatinum  	 JJ	B-NP
chemotherapeutic  	chemotherapeutic  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
is  	is  	 VBZ	O
also  	also  	 RB	O
influenced  	influenced  	 VBN	O
by  	by  	 IN	O
this  	this  	 DT	O
parameter  	parameter  	 NN	O
( 	( 	 -LRB-	O
PFI 	PFI 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Indeed 	Indeed 	 RB	O
,  	,  	 ,	O
although  	although  	 IN	O
definitive  	definitive  	 JJ	O
comparisons  	comparisons  	 NNS	O
of  	of  	 IN	O
nonplatinum  	nonplatinum  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
to  	to  	 TO	O
novel  	novel  	 VB	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
are  	are  	 VBP	O
lacking 	lacking 	 VBG	O
,  	,  	 ,	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
activity  	activity  	 NN	I-NP
of  	of  	 IN	O
these  	these  	 DT	O
compounds  	compounds  	 NN	O
might  	might  	 MD	O
approach  	approach  	 VB	O
or  	or  	 CC	O
exceed  	exceed  	 VB	O
that  	that  	 IN	O
of  	of  	 IN	O
platinum  	platinum  	 NN	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
recognized  	recognized  	 VBN	O
by  	by  	 IN	O
clinicians 	clinicians 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
dichotomy  	dichotomy  	 NN	O
that  	that  	 WDT	O
determines  	determines  	 VBZ	O
therapy  	therapy  	 VBN	O
based  	based  	 VBN	O
on  	on  	 IN	O
PFI  	PFI  	 NNP	B-NP
has  	has  	 VBZ	O
not  	not  	 RB	O
been  	been  	 VBN	O
formally  	formally  	 RB	O
accepted  	accepted  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	O
and  	and  	 CC	O
Drug  	Drug  	 NNP	B-NP
Administration  	Administration  	 NNP	I-NP
in  	in  	 IN	O
all  	all  	 DT	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
drug  	drug  	 NN	B-NP
labeling 	labeling 	 NN	I-NP
.  	.  	 .	O
For  	For  	 IN	O
instance 	instance 	 NN	O
,  	,  	 ,	O
whereas  	whereas  	 IN	O
the  	the  	 DT	O
combination  	combination  	 NN	O
of  	of  	 IN	O
gemcitabine  	gemcitabine  	 NN	B-NP
and  	and  	 CC	O
carboplatin  	carboplatin  	 NN	B-NP
is  	is  	 VBZ	O
now  	now  	 RB	O
approved  	approved  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
recurrent  	recurrent  	 JJ	I-NP
ovarian  	ovarian  	 JJ	I-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
traditionally  	traditionally  	 RB	O
used  	used  	 VBN	O
platinum-resistant  	platinum-resistant  	 JJ	O
( 	( 	 -LRB-	O
PFI  	PFI  	 NNP	B-NP
< 	< 	 SYM	O
6  	6  	 CD	O
months 	months 	 NNS	O
)  	)  	 -RRB-	O
agents  	agents  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
topotecan  	topotecan  	 NN	B-NP
and  	and  	 CC	O
pegylated  	pegylated  	 JJ	B-NP
liposomal  	liposomal  	 JJ	I-NP
doxorubicin  	doxorubicin  	 NNS	I-NP
are  	are  	 VBP	O
also  	also  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	O
and  	and  	 CC	O
Drug  	Drug  	 NNP	B-NP
Administration  	Administration  	 NNP	I-NP
as  	as  	 IN	O
single  	single  	 JJ	O
agents  	agents  	 NNS	O
in  	in  	 IN	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
nonplatinum  	nonplatinum  	 FW	B-NP
doublet  	doublet  	 FW	I-NP
pegylated  	pegylated  	 FW	O
liposomal  	liposomal  	 FW	B-NP
doxorubicin  	doxorubicin  	 FW	I-NP
and  	and  	 CC	O
trabectedin  	trabectedin  	 NN	B-NP
has  	has  	 VBZ	O
recently  	recently  	 RB	O
documented  	documented  	 VBN	O
comparable  	comparable  	 JJ	O
activity  	activity  	 NN	O
to  	to  	 TO	O
platinum  	platinum  	 NN	B-NP
combinations  	combinations  	 NNS	I-NP
among  	among  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
PFI  	PFI  	 NNP	B-NP
of  	of  	 IN	O
longer  	longer  	 JJR	O
than  	than  	 IN	O
6  	6  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
To  	To  	 TO	O
that  	that  	 DT	O
end 	end 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
most  	most  	 RBS	O
prolific  	prolific  	 JJ	B-NP
developmental  	developmental  	 JJ	I-NP
therapeutics  	therapeutics  	 JJ	I-NP
arena  	arena  	 NN	I-NP
in  	in  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
is  	is  	 VBZ	O
biologically  	biologically  	 VBN	O
targeted  	targeted  	 VBN	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
particularly  	particularly  	 RB	O
angiogenesis  	angiogenesis  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
unknown  	unknown  	 VBN	B-NP
if  	if  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
activity  	activity  	 NN	I-NP
from  	from  	 IN	O
these  	these  	 DT	O
new  	new  	 JJ	O
agents  	agents  	 NNS	O
will  	will  	 MD	O
respect  	respect  	 VB	O
the  	the  	 DT	O
chemotherapy-sensitive  	chemotherapy-sensitive  	 JJ	B-NP
dichotomy 	dichotomy 	 NN	I-NP
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
clear  	clear  	 JJ	O
that  	that  	 IN	O
they  	they  	 PRP	O
have  	have  	 VBP	O
the  	the  	 DT	O
potential  	potential  	 JJ	O
to  	to  	 TO	O
augment  	augment  	 VB	O
efficacy 	efficacy 	 NNS	O
,  	,  	 ,	O
possibly  	possibly  	 RB	O
in  	in  	 IN	O
both  	both  	 DT	O
traditionally  	traditionally  	 JJ	O
chemosensitive  	chemosensitive  	 NN	B-NP
and  	and  	 CC	O
chemoresistant  	chemoresistant  	 JJ	B-NP
phenotypes 	phenotypes 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
term  	term  	 NN	B-NP
platinum  	platinum  	 NN	I-NP
sensitive  	sensitive  	 NNS	O
should  	should  	 MD	O
probably  	probably  	 RB	O
be  	be  	 VB	O
replaced  	replaced  	 VBN	O
by  	by  	 IN	O
chemotherapy  	chemotherapy  	 JJ	O
sensitive 	sensitive 	 JJ	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
as  	as  	 IN	O
new  	new  	 JJ	O
nonplatinum  	nonplatinum  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
and  	and  	 CC	O
combinations  	combinations  	 NNS	B-NP
are  	are  	 VBP	O
identified  	identified  	 VBN	O
as  	as  	 IN	O
active  	active  	 JJ	O
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
.  	.  	 .	O
Nonplatinum  	Nonplatinum  	 JJ	B-NP
doublets  	doublets  	 NNS	I-NP
are  	are  	 VBP	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
treating  	treating  	 VBG	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
recurrent  	recurrent  	 JJ	I-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
adding  	adding  	 VBG	O
antiangiogenesis  	antiangiogenesis  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
to  	to  	 TO	O
these  	these  	 DT	O
combinations  	combinations  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
research  	research  	 NN	O
priority 	priority 	 NN	O
.  	.  	 .	O
